This scheme provides long-term support for established researchers to pursue an ambitious and creative programme of work addressing key questions in the cancer field. Proposals should be centred on a core overarching vision, explored via a set of connected aims. We encourage collaborative teams and multidisciplinary approaches.
Timelines
Applications are reviewed twice per year. Upcoming application deadline (outline): 29 September 2026
Funding period
5 years
Funding amount
Up to £2.5m
The applicant
You can apply to this award if you’re a scientist, clinician or healthcare worker based in a UK university, medical school, hospital or research institution.
You can hold this award if you’ve had funding from us before, but prior funding is not a requirement.
During the full duration of the award, you must be in a post that is fully funded by the relevant national Higher Education Funding Council, the National Health Service or equivalent. Please note that Programme Awards cannot be used to fund part of an applicant's salary.
1. Strong scientific excellence and innovation
The strongest CRUK applications typically demonstrate:
CRUK explicitly encourages “bold and creative applications.”
2. Clear translational and patient impact
CRUK reviewers strongly favor projects likely to:
Applications with a realistic pathway toward patient benefit are highly competitive.
3. Strong preliminary data
Competitive applications usually include:
Strong preliminary evidence substantially improves reviewer confidence.
4. Rigorous methodology and feasibility
Successful proposals generally demonstrate:
Weak feasibility or underpowered study design is a common reason for rejection.
5. Strong collaborative and multidisciplinary teams
High-scoring CRUK projects frequently involve:
Cross-institutional collaboration is particularly valued in major CRUK schemes.
6. Strong publication and academic track record
Important predictors include:
Track record remains one of the strongest predictors across major CRUK schemes.
7. Alignment with CRUK strategic priorities
Applications aligned with CRUK priorities tend to perform better, especially:
8. Strong translational infrastructure
Reviewers favor applicants with access to:
Institutional infrastructure strongly influences feasibility assessments.
9. Potential for long-term impact and scalability
Competitive proposals are often those likely to:
CRUK prioritizes research with broad and durable oncology impact.
10. Leadership and future funding potential
For fellowships and career awards, reviewers heavily assess:
Career-development planning is particularly important for early-career investigators.
Frequent reviewer concerns include:
Our core eligibility criteria are outlined below. Note that this scheme operates with closed rounds to ensure only eligible applications are submitted.
You must contact us for an informal and confidential discussion of your proposal prior to submitting your application. We’ll advise on your eligibility and provide guidance on submitting your application.
Sponsor Institute/Organizations: Cancer Research UK
Sponsor Type: Corporate/Non-Profit
Address: 2 Redman Place, London, E20 1JQ.
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Sep 29, 2026
$3,375,000
Affiliation: Cancer Research UK
Address: 2 Redman Place, London, E20 1JQ.
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.